This phase I trial studies the side effects of pembrolizumab in treating patients with human immunodeficiency virus (HIV) and malignant neoplasms that have come back (relapsed), do not respond to treatment (refractory), or have distributed over a large area in the b...
- Sarcoma, Kaposi
- Lymphoma
- Carcinoma
- Lung Neoplasms
- Neoplasms
- Melanoma
- Sarcoma
- Hodgkin Disease
- Skin Neoplasms
- Carcinoma, Non-Small-Cell Lung
- Neoplasm Metastasis
- Recurrence
Age: 18 years - 66+
Gender: All